ORLANDO, Florida — An analysis of data from 137 patients suggested testing whether people have a trait known as abnormal postprandial satiety , or hungry gut, can predict how well they may respond to the obesity drug semaglutide, although it failed to establish this link for the somewhat similar tirzepatide.
At 12 months, among those taking semaglutide, patients classified as APS+ achieved a mean 18% body weight loss compared with 10% in those classified as APS−. But the test didn't find these kinds of differences for the tirzepatide group, with a mean 19.4% body weight loss in the APS+ group and a mean loss of 22.1% in the APS− group.
Daniel S. Hsia, MD, of Emory University, Atlanta, Georgia, who led the ADA session at which Hurtado presented, said it was good to see new information being presented about using genetic risk scoring in obesity.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: MedicineNet - 🏆 575. / 51 Read more »